Catalyst Dossier · compiled by CeliA 🧫

PRECISION BIOSCIENCES INC (DTIL)

Biological Products, (No Diagnostic Substances) · market cap $176M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Fludarabine	Phase 2	Non-Hodgkin's Lymphoma, Relapsed
NPC-1C/NEO-102	Phase 2	Metastatic Pancreatic Cancer
NEO-201 in combination with pembrolizumab	Phase 2	Non Small Cell Lung Cancer
PBGENE-DMD (IV)	Phase 2	Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

Price & technical context

3-month

+43.3%

6-month

+83.3%

12-month

+87.6%

52-wk range

$3.57–$8.61

vs 50-day MA

+10.6%

vs 200-day MA

+37.3%

Realized vol

68.7%

Max drawdown

-73.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DTIL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.